articles and announcements

LADDER Database Receives Transformational Dataset from Ovid Therapeutics

Ovid Therapeutics
September 2, 2022

LADDER Database Receives Transformational Dataset from Ovid Therapeutics

Angelman Syndrome Foundation (ASF) proudly announces the collaboration with OVID Therapeutics to advance understanding of AS via a contribution of crucial data collected in Ovid’s clinical trial for Angelman syndrome to the LADDER database.

“The most important gift that industry can give to the community is data to help us understand AS better and expedite the possibility of a therapeutic treatment. We are hoping that Ovid is setting a standard of excellence and transparency for other developers to be willing to give data back to the community,” Amanda Moore, CEO of ASF.

The goal of the LADDER database, which is funded by the Angelman Syndrome Foundation, is to link data on individuals with Angelman or Dup15q syndromes collected from multiple sources, such as research studies, registries, caregiver reports and clinic visits. Ovid has committed to provide baseline data from NEPTUNE, one of the largest clinical development programs conducted within Angelman syndrome.

“Ovid was the first company to initiate therapeutic development in Angelman syndrome, and it continues to be our privilege to collaborate with the families, children, physicians and researchers within the community. To help further scientific and therapeutic understanding of Angelman syndrome, we are proud to share baseline data from our NEPTUNE program with LADDER. Responsible and transparent data sharing are critical to enhancing collective understanding in the field and therapeutic discovery and development for rare neurological conditions. We thank all those who have participated in the NEPTUNE trial and genuinely hope that this data sharing commitment will advance research and therapeutics that meaningfully benefit these incredible families,” said Jeremy M. Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid.

The information provided by Ovid to LADDER includes de-identified, baseline data for U.S. patients who participated in Ovid’s NEPTUNE trial program.  Any data provided to LADDER by Ovid must accord with RTI Institutional Review Board (IRB) standards for the protection of clinical trial participant confidentiality. LADDER must also maintain agreed upon standards to prevent the unauthorized or inappropriate use of the data. 

 

ABOUT LADDER DATABASE

Linking Angelman and Dup15q Data for Expanded Research (LADDER) is a database platform that links data on individuals with Angelman or Dup15q syndromes collected from multiple sources, such as research studies, registries, caregiver reports, and clinic visits. By linking these sources of information, LADDER can expand research and accelerate the development of interventions and treatments for individuals with Angelman or Dup15q and their families.